| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5608489 | Journal of the American College of Cardiology | 2017 | 9 Pages |
Abstract
Posaconazole demonstrated trypanostatic activity during treatment, but it is ineffective long-term in asymptomatic T. cruzi carriers. Benznidazole monotherapy is superior to posaconazole, with high RT-PCR conversion rates sustained at 1 year. Side effects lead to therapy discontinuation in 32%. No advantages were observed with combined therapy versus benznidazole monotherapy. (A Study of the Use of Oral Posaconazole [POS] in the Treatment of Asymptomatic Chronic Chagas Disease [P05267] [STOP CHAGAS]: NCT01377480)
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Carlos A. MD, Hetty MD, PhD, Sergio MD, Maria MD, Carlos MD, Rodolfo MD, Marcelo MD, Werner MD, PhD, Juan MD, Joaquim MD, PhD, Israel MD, PhD, Luis E. MD, Hugo MD, Jose Antonio MD, PhD, Fernando MD, Brandi MEng, Laura R. MSc, Peggy MSc,